Showing results (11-20 of 127) with videos related to
Sort By:
Pageof 13
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 27, 2015
Minimal residual disease in cancer therapy--Small things make all the differenceSohvi Blatter, Sven RottenbergBreast Cancer Research : BCR|November 7, 2012
MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expressionSven Rottenberg, Jos JonkersVeterinary Sciences|September 27, 2025
Advancing In Vitro Tools for Oncologic Research in Cats and DogsChang He, Sven RottenbergDrug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|March 4, 2018
New tools for old drugs: Functional genetic screens to optimize current chemotherapyNora M Gerhards, Sven RottenbergThe EMBO Journal|August 9, 2019
DNA damage kinase signaling: checkpoint and repair at 30 yearsMichael Charles Lanz, Diego Dibitetto, Marcus Bustamante SmolkaNature Reviews. Cancer|October 31, 2020
The rediscovery of platinum-based cancer therapySven Rottenberg, Carmen Disler, Paola PeregoCell Cycle (Georgetown, Tex.)|April 18, 2008
How do real tumors become resistant to cisplatin?Piet Borst, Sven Rottenberg, Jos JonkersCurrent Opinion in Microbiology|August 28, 2003
Theileria-induced leukocyte transformationDirk A E Dobbelaere, Sven RottenbergMethods in Molecular Biology (Clifton, N.J.)|December 2, 2009
Studying drug resistance using genetically engineered mouse models for breast cancerSven Rottenberg, Marina Pajic, Jos JonkersCell Cycle (Georgetown, Tex.)|November 14, 2007
What makes tumors multidrug resistant?Piet Borst, Jos Jonkers, Sven RottenbergPageof 13